Dedicated High-Performance Breast PET/CT

目的：研制一种高性能、高分辨率的定量PET/CT扫描仪 致力于乳房成像。这将允许验证解剖代谢成像， 局部分期背景下的乳腺，治疗反应的预测，随访 用于接受保守治疗的患者和开发用于乳腺癌的新药 癌症治疗 方法：采用新型高分辨率、低死区闪烁探测器设计 使用使用APD和PSPMT的双端读出方案，以及修改版本 商业PET电子，我们将建立一个PET扫描仪足够紧凑，以适应内部 我们现有的乳房CT扫描仪的机架。我们将联合收割机结合起来， 在相同的临床环境中对乳房进行连续成像， 配准的高分辨率功能和解剖图像。该设备将兼容 具有活检工具，可扩展以便于胸壁成像， 腋窝建设将分阶段进行。在每个阶段，我们将使用连续测试/重新测试 使用预先计算的基准点，以便有效和及时地解决 出现的问题。我们将采用最先进的图像重建技术， 测量系统模型，以最大限度地提高空间分辨率，我们将认真实施 所有必要的数据校正定量成像。我们将比较性能 在30名已知患有乳腺癌的患者中进行全身PET/CT和MRI试验。 健康相关性：迄今为止在诊所测试的乳腺PET成像仪成本低， 无法充分评估体内方法的低性能器械，以及 不提供与3D解剖信息融合的3D图像（一种很好的技术， 在身体上证明）。因此，分子成像在分期和再诊断方面的已知能力是有限的。 分期，对治疗研究和药物开发的反应， 女性原发性乳腺癌的比例。拟议中的设备将解决这一问题 问题，并允许确定足够的最低成像要求 临床性能-这是将该技术转化为患者护理的先决条件。

Objectives: To build a high-performance, high-resolution quantitative PET/CT scanner dedicated to imaging the breast. This will permit validation of anato-metabolic imaging of the breast in the contexts of local staging, prediction of therapeutic response, follow-up for patients receiving conservative therapy and the development of new drugs for breast cancer treatment. Methods: Using a novel high-resolution, low-dead-time scintillation detector design using a dual-ended read-out scheme using APDs and PSPMTs, and a modified version of commercial PET electronics, we will build a PET scanner compact enough to fit inside the gantry of our existing breast CT scanner. We will combine the two devices to allow sequential imaging of the breast in the same clinical setting, resulting in accurately registered high-resolution functional and anatomic images. The device will be compatible with biopsy tools and will be expandable to facilitate imaging of the chest wall and axillae. Construction will be phased. At each stage we will use a continuous test/re-test approach using pre-calculated bench-marks to permit efficient and timely resolution of arising issues. We will employ state-of-the-art image reconstruction techniques using measured system models to maximize spatial resolution, and we will carefully implement all necessary data corrections for quantitative imaging. We will compare performance with whole-body PET/CT and MRI in a trial of 30 patients with known breast cancer. Health relatedness: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care.